Vistagen Therapeutics (VTGN) Operating Leases (2019 - 2025)
Historic Operating Leases for Vistagen Therapeutics (VTGN) over the last 7 years, with Q4 2025 value amounting to $431000.0.
- Vistagen Therapeutics' Operating Leases fell 6117.12% to $431000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $431000.0, marking a year-over-year decrease of 6117.12%. This contributed to the annual value of $948000.0 for FY2025, which is 3961.78% down from last year.
- According to the latest figures from Q4 2025, Vistagen Therapeutics' Operating Leases is $431000.0, which was down 6117.12% from $610000.0 recorded in Q3 2025.
- In the past 5 years, Vistagen Therapeutics' Operating Leases ranged from a high of $3.6 million in Q2 2021 and a low of $431000.0 during Q4 2025
- Its 5-year average for Operating Leases is $1.9 million, with a median of $1.9 million in 2023.
- Its Operating Leases has fluctuated over the past 5 years, first tumbled by 823.14% in 2021, then tumbled by 6117.12% in 2025.
- Quarter analysis of 5 years shows Vistagen Therapeutics' Operating Leases stood at $2.7 million in 2021, then dropped by 17.31% to $2.2 million in 2022, then decreased by 23.74% to $1.7 million in 2023, then plummeted by 35.21% to $1.1 million in 2024, then plummeted by 61.17% to $431000.0 in 2025.
- Its Operating Leases stands at $431000.0 for Q4 2025, versus $610000.0 for Q3 2025 and $783000.0 for Q2 2025.